Advice

Following an abbreviated submission

Ezetimibe/simvastatin (InegyP®P) is accepted for restricted use in NHS Scotland only for patients who have failed to achieve target cholesterol levels after titration and optimisation of statin monotherapy and where the combination of ezetimibe 10mg and simvastatin 20mg, 40mg or 80mg is appropriate.

This reflects advice on ezetimibe issued by the Scottish Medicines Consortium in September 2003 (61/03) and is based on the combined tablets being priced at approximately the same level as the individual ingredients.

Download detailed advice33KB (PDF)

Download

Medicine details

Medicine name:
ezetimibe/simvastatin (Inegy)
SMC ID:
182/05
Indication:
Hypercholesterolaemia and Homozygous Familial Hypercholesterolaemia
Pharmaceutical company
MSD/Schering Plough
BNF chapter
Cardiovascular system
Submission type
Abbreviated
Status
Restricted
Date advice published
13 June 2005